Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 14/20 | 0.36 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1481864 | 0.68 | KIF11 (0.39) | CYP1A2CYP2C9CYP2C19SIRT2KCNA5 | |
| SCHEMBL13053078 | 0.68 | CYP11B1 (0.42) | CYP2C19SIRT2ENPP2CYP3A4CYP11B1 | |
| SCHEMBL27975355 | 0.65 | CYP11B1 (0.49) | CYP1A2CYP2C9CYP2C19SIRT2ENPP2 | |
| SCHEMBL2105404 | 0.65 | SIGMAR1 (0.38) | SIRT2CYP11B1CYP11B2 | |
| SCHEMBL1342 | 0.64 | SIRT2 (0.45) | SIRT2ENPP2CYP11B1CYP11B2 | |
| SCHEMBL6771514 | 0.63 | SIRT2 (0.44) | SIRT2ENPP2CYP11B1CYP11B2 | |
| SCHEMBL6553669 | 0.62 | CYP11B1 (0.39) | SIRT2ENPP2CYP11B1CYP11B2 | |
| SCHEMBL3746941 | 0.62 | KDM4E (0.33) | SIRT2ENPP2HPGDHIF1A | |
| SCHEMBL1041048 | 0.62 | SIRT2 (0.49) | SIRT2ENPP2CYP11B1CYP11B2 | |
| SCHEMBL10187011 | 0.62 | SIRT2 (0.46) | SIRT2ENPP2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838545-B2 | 4-(condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists | ALLERGAN, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| US-20090176828-A1 | 4-(CONDENSED CYCLICMETHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS | ALLERGAN, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7396849-B2 | 4-(Condensed cyclicmethyl)-imidazole-2-thiones acting as α2 adrenergic agonists | ALLERGAN, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| EP-1791833-A2 | 4-(CONDENSED CYCLICMETHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS | Allergan, Inc. (US) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006036497-A2 | 4-(CONDENSED CYCLICMETHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS | ALLERGAN, INC. (US) | 2006-04-06 | — | — | WO | disclosed |
| US-20060069144-A1 | 4-(Condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists | ALLERGAN, INC. | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069144-A1 | 4-(Condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists | ADRB2, ADRA2C, ADRA2A | CYP1A2 173/4885CYP2C9 1227/4885CYP2C19 1064/4885 |
| US-20090176828-A1 | 4-(CONDENSED CYCLICMETHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS | ADRB2, ADRA2C, ADRA2A | CYP1A2 103/4885CYP2C9 921/4885CYP2C19 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.